Sight Sciences (SGHT) to Release Quarterly Earnings on Thursday

Sight Sciences (NASDAQ:SGHT) is projected to announce its Q2 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $18.18 million for the quarter. Sight Sciences has set its FY 2025 guidance at EPS.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.01. The business had revenue of $17.51 million for the quarter, compared to the consensus estimate of $16.51 million. Sight Sciences had a negative net margin of 63.24% and a negative return on equity of 54.62%. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sight Sciences Stock Performance

Shares of NASDAQ:SGHT opened at $3.49 on Wednesday. The company has a market capitalization of $180.43 million, a price-to-earnings ratio of -3.56 and a beta of 2.44. The firm’s 50 day simple moving average is $3.84 and its 200 day simple moving average is $3.15. The company has a debt-to-equity ratio of 0.51, a current ratio of 10.47 and a quick ratio of 9.99. Sight Sciences has a fifty-two week low of $2.03 and a fifty-two week high of $7.05.

Analysts Set New Price Targets

A number of analysts recently weighed in on SGHT shares. Lake Street Capital increased their price target on shares of Sight Sciences from $2.50 to $3.00 and gave the company a “hold” rating in a research report on Friday, May 9th. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research note on Wednesday, April 9th. Piper Sandler reissued a “neutral” rating and set a $4.00 target price (up from $3.50) on shares of Sight Sciences in a research note on Wednesday, June 18th. Wall Street Zen cut Sight Sciences from a “hold” rating to a “sell” rating in a research note on Friday, July 18th. Finally, Morgan Stanley increased their target price on Sight Sciences from $3.00 to $4.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Sight Sciences presently has an average rating of “Hold” and a consensus price target of $3.93.

Insider Buying and Selling

In other news, insider Jeremy B. Hayden sold 9,160 shares of the firm’s stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $4.17, for a total transaction of $38,197.20. Following the completion of the transaction, the insider directly owned 266,321 shares of the company’s stock, valued at $1,110,558.57. This trade represents a 3.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Paul Badawi sold 23,637 shares of the firm’s stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $4.15, for a total transaction of $98,093.55. Following the transaction, the chief executive officer directly owned 5,986,943 shares of the company’s stock, valued at $24,845,813.45. This represents a 0.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 43,365 shares of company stock valued at $180,017. 28.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Sight Sciences

Several hedge funds have recently made changes to their positions in SGHT. Strs Ohio bought a new position in shares of Sight Sciences during the 1st quarter worth approximately $158,000. AQR Capital Management LLC bought a new position in shares of Sight Sciences during the 1st quarter worth approximately $128,000. Finally, Rhumbline Advisers grew its stake in shares of Sight Sciences by 9.5% during the 1st quarter. Rhumbline Advisers now owns 49,797 shares of the company’s stock worth $120,000 after acquiring an additional 4,319 shares in the last quarter. 55.51% of the stock is owned by institutional investors.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.